NEW YORK (GenomeWeb News) – Clinical Data today said that it has completed a $50 million convertible debt financing with New River Management V and another affiliate of Randal J. Kirk, chairman of Clinical Data's board of directors.

The Newton, Mass.-based firm, which makes pharmacogenetic tests and is developing therapeutics, said that the funds would be used primarily to support late-stage therapeutics development. It has two compounds in Phase III studies: vilazodone for treating depression, and Stedivaze, a cardiac stress agent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.